US, Russia reach deal on Syrian chemical weapons

September 14, 2013

Geneva, Sep 14: U.S. Secretary of State John Kerry and Russian Foreign Minister Sergey Lavrov reached agreement on Saturday on a framework for Syria to destroy all of its chemical weapons, and said they would seek a U.N. Security Council resolution that could authorize sanctions short of military action if President Bashar Assad's government fails to comply.Kerry-Lavrov

The deal announced by the diplomats on the third day of intense negotiations in Geneva includes what Kerry called “a shared assessment” of Syria's weapons stockpile, and a timetable and measures for Syria to comply.

The deal calls for international inspectors to be on the ground in Syria by November and to complete their initial work by the end of that that month. All of Syria's chemical weapons stocks, material and equipment would have to be destroyed or removed by mid-2014.

But the stakes have been especially high in Geneva, because the negotiations between the United States and Russia on securing Syria's chemical weapons also are considered key to breaking the international stalemate that has so far blocked a resumption of peace talks to end the Syrian civil war, now in its third year.

“We have committed to a standard that says, verify and verify,” Mr Kerry told a packed news conference in the Intercontinental Hotel in Geneva, where he has been staying and the negotiations were conducted since Thursday night.

Among the highlights of the agreement is that the U.S. and Russia would agree to work together on a new, binding Security Council resolution that would ensure verification of the agreement to secure and destroy Syria's chemical weapons stocks and remove its capability to produce such weapons.

The resolution would allow for punitive measures for non-compliance, but stop short of military action, if the 16-nation Security Council approves them. The U.S. and Russia are two of the five permanent Security Council members with a veto. The others are Britain, China, and France.

Another major feature of the agreement is that the U.S. and Russia plan to give Syria one week, until Sept. 21, to submit “a comprehensive listing, including names, types and quantities of its chemical weapons agents, types of munitions, and local and form of storage, production, and research and development facilities.”

In addition, the U.S. and Russia have agreed that international inspectors should be on the ground in Syria by November and complete their initial work by the end of the month. They must be given “immediate and unfettered” access to inspect all sites.

Notably, Mr Kerry said they had agreed on grounds under which they might request a Security Council “Chapter 7” resolution at the United Nations, which is a measure that could include military and non-military sanctions.

But Mr Lavrov, who said the agreement was “based on consensus and compromise and professionalism,” indicated there would be limits to using a Chapter 7 resolution, which Russia would almost certainly veto if it specifically authorized a military strike such as what President Barack Obama has threatened.

“Any violations of procedures ... would be looked at by the Security Council and if they are approved, the Security Council would take the required measures, concrete measures,” Mr Lavrov said.

“Nothing is said about the use of force or about any automatic sanctions. All violations should be approved by the Security Council,” he added.

Mr Kerry also said any violations will result in “measures” from the Security Council, while Mr Lavrov said the violations must be sent to the Security Council from the board of the chemical weapons convention before sanctions short of the use of force would be considered.

Mr Kerry said the pair and their teams of experts had come to agreement on the exact size of Syria's weapons stockpile, which had been a sticking point before their meetings in Geneva. But in marathon sessions into early morning hours, the U.S. and Russia succeeded in narrowing their differences.

The agreement over the Russian proposal to inventory, isolate and eventually destroy Syria's chemical weapons stocks comes as the Obama administration warned that there is a timetable for a diplomatic resolution of the weapons issue.

DPA adds

Meanwhile, the rebel Free Syrian Army (FSA) has rejected a U.S.-Russian deal on dismantling Syria's chemical weapons and has vowed to continue fighting to oust President Bashar al-Assad.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 10,2020

Melbourne, Apr 10: Scientists have identified six drug candidates from more than 10,000 compounds that may help treat COVID-19.

The research, published in the journal Nature, tested the efficacy of approved drugs, drug candidates in clinical trials and other compounds.

"Currently there are no targeted therapeutics or effective treatment options for COVID-19," said Professor Luke Guddat from the University of Queensland in Australia.

"In order to rapidly discover lead compounds for clinical use, we initiated a programme of high-throughput drug screening, both in laboratories and also using the latest computer software to predict how different drugs bind to the virus," Guddat said.

The project targeted the main COVID-19 virus enzyme, known as the main protease or Mpro, which plays a pivotal role in mediating viral replication, the researchers said.

This makes it an attractive drug target for this virus, and as people don't naturally have this enzyme, compounds that target it are likely to have low toxicity, they said.

"We add the drugs directly to the enzyme or to cell cultures growing the virus and assess how much of each compound is required to stop the enzyme from working or to kill the virus. If the amount is small, then we have a promising compound for further studies," said Guddat.

After assaying thousands of drugs, researchers found of the six that appear to be effective in inhibiting the enzyme, one is of particular interest.

"We're particularly looking at several leads that have been subjected to clinical trials including for the prevention and treatment of various disorders such as cardiovascular diseases, arthritis, stroke, atherosclerosis and cancer," Guddat said.

Researchers said compounds that are already along the pipeline to drug discovery are preferred, as they can be further tested as antivirals at an accelerated rate compared to new drug leads that would have to go through this process from scratch.

"With continued and up-scaled efforts we are optimistic that new candidates can enter the COVID-19 drug discovery pipeline in the near future," Guddat said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 24,2020

The total number of global coronavirus cases has topped 15.4 million, while the deaths have increased to over 631,000, according to the Johns Hopkins University.

As of Friday morning, the total number of cases stood at 15,439,456, while the fatalities rose to 631,926, the University's Center for Systems Science and Engineering (CSSE) revealed in its latest update.

The US accounted for the world's highest number of infections and fatalities at 4,034,831 and 144,242, respectively, according to the CSSE.

Brazil came in the second place with 2,287,475 infections and 84,082 deaths.

In terms of cases, India ranks third (1,238,798), and is followed by Russia (793,720), South Africa (408,052), Peru (371,096), Mexico (370,712), Chile (334,683), the UK (298,721), Iran (284,034), Spain (270,166), Pakistan (269,191), Saudi Arabia (260,394), Italy (245,338), Turkey (223,315), Colombia (218,428), France (216,667), Bangladesh (216,110), Germany (204,881), Argentina (148,027), Canada (114,398), Qatar (108,244) and Iraq (102,226), the CSSE figures showed.

The other countries with over 10,000 deaths are the UK (45,639), Mexico (41,908), Italy (35,092), France (30,185), India (29,861), Spain (28,429), Iran (15,074), Peru (17,654) and Russia (12,873).

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.